| Literature DB >> 33913876 |
Mallika Goyal1, Somasheila I Murthy2, Sridhar Annum1.
Abstract
PURPOSE: To describe retinal manifestations seen in patients associated with COVID-19 infection at a multi-specialty tertiary care hospital in Southern India.Entities:
Keywords: COVID 19; COVID-associated mycoses; endophthalmitis; ocular manifestations; paracentral acute middle maculopathy; retinal manifestations
Mesh:
Year: 2021 PMID: 33913876 PMCID: PMC8186578 DOI: 10.4103/ijo.IJO_403_21
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Clinical characteristics of the seven patients
| Case | Age/Gender | Eye | COVID Infection timeline | Use of steroids | Systemic disease, status, investigations | Onset and duration of symptoms | Vision | Examination | Diagnosis | Treatment | Final outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 42/M | RE | 6 weeks prior to ocular symptoms | Intravenous steroids for five days | Steroid induced diabetes | Onset: while on COVID treatment 4 weeks duration | Hand movements | Conjunctival congestion, cells 3+, hypopyon, dense vitreous exudates, fungal balls | Fungal endophthalmitis (microbiology negative) | Pars plana vitrectomy + intravitreal antifungals followed by oral antifungals for 6 weeks | Resolved with 6/9 vision |
| 2 | 75/M | RE | Not available | Not available | Candida septicemia, and candida renal infection during COVID 19, blood and urine cultures positive. Generalized compromised status | Not noticed by the patient | Counting fingers at 2 meters | 2+cells, 1+vitreous cells three retinitis lesions | Candida retinitis | Oral fluconazole and voriconazole for 6 weeks, followed by intravitreal Amphotericin B and voriconazole | 6/36, slow response |
| 3 | 59/F | RE | COVID-19 infection two months prior | Oral steroids used for 4 weeks | Nocturnal pyrexia, whole body imaging revealed splenic abscesses | 4 weeks | 6/9 | 1+ vit cells, choroidal abscess with scarring of edges and miliary lesions | Intraocular tuberculosis | Anti-tubercular therapy, lesions resolving over 6 weeks | 6/6 |
| 4 | 32/M | Both eyes | COVID 4 months ago | No | Nil | 3 days | 6/6 | Bilateral greyish white retinal lesions | Acute Macular Neuroretinopathy (AMN) and Paracentral Acute Middle Maculopathy (PAMM) | Observation | 6/6 |
| 5 | 27.F | LE | COVID-19 infection two weeks prior | On oral steroids for one week | Nil | One week | 6/18 | Serous detachment of macula | CSCR | NIL | 6/6 |
| 6 | 32/F | BES | COVID infection 6 weeks prior | Yes | Pseudomonas sepsis and thrombocytopenia, admitted in intensive care unit | One month | Counting fingers at 4 meters | Bilateral prefoveal hemorrhages | Retinal hemorrhages | NIL | 6/18 and 6/36 |
| 7 | 40/M | BES | COVID infection 6 weeks prior | Yes | Intensive care unit admission for systemic aspergillosis, status post renal transplant and Diabetes mellitus | 3 weeks | 6/6 | Normal examination, visual fields: normal | Voriconazole induced transient visual disturbance | Decreasing the dose of voriconazole, recovery for one week followed by relapse after resuming therapy | 6/6 |
Figure 1(a) Intraoperative photograph of the right eye shows severe ciliary congestion and hypopyon. (b) Intra-operative photograph during pars plana vitrectomy shows dense and dry vitreous lesions (asterisk) (c) Snowball like opacities noted in the inferior periphery (d) Same eye shows compete resolution with clear media and normal fundus at 6 weeks
Figure 2(a-k) Creamy-white candida retinitis lesions at presentation (a), macular involvement (b) Two weeks after voriconazole (c) Six weeks later: increasing activity (d and e) 10 days after intravitreal injections new vitreous exudates are noted (f); older retinitits lesions show some resolution (g)The lesions and vitreous exudates persist with some resolution after 4 weeks of injections. 3 months review: complete resolution of vitreous inflammation and retinitis, (j-l) with scarring noted at the site of the original lesions
Figure 3(a) Large choroidal abscess with active appearing center and resolving activity at edges supero-temporal to the right macula. (b and c) Multiple miliary lesions around the choroidal abscess in temporal and inferotemporal fundus. Lesions are larger and irregular closer to the abscess, becoming smaller, punctate with smoother edges further from it. (d) OCT showing epiretinal membrane and vitreous traction over the choroidal abscess. (e and f) Significant resolution of choroidal abscess and miliary lesions 6 weeks after initiating anti-tubercular therapy
Figure 4(a) Triangular greyish-white lesion (asterisk) of AMN (b) Corresponding OCT shows disruption of external retinal layers (c and d) Focal areas of hyper-reflectivity with deeper shadowing of PAMM. (e) OCT right eye: diffuse hyper-reflectivity of entire inner retinal surface (f) Small greyish-white lesions in superficial retina nasal, inferonasal and temporal to the foveal center in left eye. (g) Corresponding OCT shows hyper-reflective lesion with underlying shadowing (h) OCT left eye showing diffuse hyper-reflectivity of the inner retinal surface
Figure 5OCT left eye of a young female treated with oral steroids for COVID-19 showing serous macular detachment
Figure 6Bilateral pre-foveal hemorrhage of the right (a) and left eye (b) in a young lady with post COVID-19 sepsis. OCT of the right eye (c) and left eye (d) showing pre-foveal location of the hemorrhage with underlying shadowing. One month later, there is almost complete resolution of the pre-foveal heme in the RE (e) and LE (f) Corresponding optical coherence tomography scans show residual paracentral pre-foveal heme in the RE (g) and intra-retinal heme in the LE (h)